How Wegovy causes weight loss — and what that means for you

Why the decision to use Wegovy starts with understanding your own hunger

A lot of people who consider Wegovy have already tried cutting calories, changing what they eat, or increasing exercise, sometimes repeatedly. The frustrating truth, supported by a growing body of research, is that sustained weight loss is genuinely hard when the body's hormonal system is actively pushing back. Hunger isn't purely willpower. It is regulated by signals that pass between the gut, the bloodstream and the brain, and those signals are often set in ways that favour weight regain after loss.

That is the context in which Wegovy makes most sense. Rather than relying on a person to override those signals through effort alone, the medicine works with the hormonal system directly. If you are asking whether Wegovy does actually cause weight loss, that question is worth exploring properly before deciding whether this kind of treatment fits your circumstances, and what role lifestyle changes still play alongside it. The semaglutide overview covers the broader context of how this drug class works across different conditions.

It also helps to understand the decision point clearly: Wegovy is not a supplement or a short-cut. It is a regulated prescription medicine, and prescribers assess factors including your weight, health history and any medicines you already take before recommending it.

What GLP-1 does, and why semaglutide borrows its shape

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases naturally after you eat, and its job is to tell your body that food has arrived. It does this in several ways at once: it signals the pancreas to release insulin, it slows gastric emptying so food moves more gradually from the stomach into the small intestine, and it travels to the brain where it damps down appetite.

Semaglutide, the active ingredient in Wegovy, is a molecule designed to look enough like GLP-1 that it binds to the same receptors. The key difference is durability. Natural GLP-1 breaks down within a few minutes. Semaglutide is engineered to resist that breakdown, which is why a single weekly injection can produce effects that last across the whole week. The result is a sustained reduction in appetite and a prolonged sense of fullness, not a blunted taste for food, but a genuine shift in the hunger signals that normally prompt eating. Understanding how semaglutides bring about weight loss at a hormonal level can help clarify why this approach differs from simply eating less. You can explore the pharmacology further in our page on how semaglutide causes weight loss.

The NHS notes that semaglutide works by activating these GLP-1 receptors to reduce appetite and slow gastric emptying, a mechanism described in detail in the NHS medicines information for semaglutide.

What the clinical evidence actually showed

The STEP 1 trial (a 68-week randomised controlled trial published in the New England Journal of Medicine) is the foundational evidence for Wegovy's weight-management licence. Participants were adults with obesity or overweight plus a weight-related condition, without type 2 diabetes. They received either semaglutide 2.4mg weekly or a placebo, alongside lifestyle counselling. The semaglutide group lost an average of around 15% of their body weight. The placebo group lost around 2.4%. That difference is clinically significant, and it reflects the mechanism above: when hunger signals are consistently quieted over months, cumulative energy intake falls and the body draws on its reserves.

What the trial also showed is that the medicine worked best alongside dietary and activity changes, not instead of them. The people in the trial received structured lifestyle support. That is worth bearing in mind when setting expectations. A prescriber can help you understand what realistic progress might look like given your own starting point. For a fuller picture of outcomes, see our Wegovy weight loss results page.

One practical note on routine: Wegovy comes as a pre-filled weekly injection pen, stored in the fridge. Many people find it easiest to keep the current pen in the fridge door (somewhere visible) and set a weekly reminder so the routine becomes automatic rather than something that requires thought each time. The dose starts low and the prescriber titrates it upward over several months, which is how the known gastrointestinal side effects are generally kept manageable.

On cost, it is worth knowing that private treatment costs vary; the weight-loss treatments page shows current pricing at nume, where one transparent fee covers the consultation, prescription, and free next-working-day delivery.

What this means when you are thinking about starting

If you have reached this page weighing up whether Wegovy is appropriate for you, the mechanism itself is only part of the picture. Equally relevant is whether you meet the eligibility criteria, whether any other medicines you take might interact, and whether the weekly injection format suits your lifestyle. The UK licence for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside a weight-related health condition such as high blood pressure or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.

A GPhC-registered prescriber at an online pharmacy will review all of that before any prescription is issued. At nume, a real clinician reads every consultation the same day, not software, and not a templated assessment. Our clinical team oversees every prescription. If you have questions before you start, the FAQs cover the most common ones, and you can always get in touch directly.

The STEP 1 trial evidence is summarised in the NICE technology appraisal for semaglutide (NICE TA875) which sets out the clinical basis on which semaglutide is recommended for weight management in the UK. When you feel ready to take the next step, you are welcome to start your free consultation.